The biochemical and cellular changes that occur following administration of 1-methyl-4-
phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) are remarkably similar to that seen in idiopathic …

It is now well recognized that 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine (MPTP) can
induce a syndrome in human and non‐human primates similar to Parkinson's disease. This …

Experimental models of dopaminergic neurodegeneration play a critical role in our quest to
elucidate the cause of Parkinson's disease (PD). Despite the recent development of “genetic …

Abstract Systemic administration of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)
gives rise to motor deficits in humans and other primates which closely resemble those seen …

Among the most widely used models of Parkinson's disease (PD) are those that employ
toxins, especially 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Depending on the …

Animal models are a very important approach to study the pathogenesis and therapeutic
intervention strategies of human diseases. Since many human disorders do not arise …

Parkinson's disease (PD) is a common disabling neurodegenerative disorder the cardinal
clinical features of which include tremor, rigidity and slowness of movement (Fahn and …

Parkinson's disease (PD) is a common neurodegenerative disorder, characterized by the
progressive loss of dopaminergic neurons in the substantia nigra. Although valuable animal …

Conclusion The discovery that a rather simple chemical substance can produce such a
highly selective neuronal degeneration in the substantia nigra, the brain area most affected …

1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) causes damage to substantia nigra
pars compacta (SNpc) dopaminergic (DA) neurons as seen in Parkinson's disease (PD) …